NCT02471196已完成2 期
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 308
- 试验地点
- 1
- 主要终点
- Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale
研究概览
简要总结
This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.
详细描述
ORM-12741 is a potent and selective alpha-2C adrenoceptor (AR)-antagonist. Previous results suggest that the compound may have positive effects on both cognitive and neuropsychiatric symptoms of Alzheimer's Disease. In this study, the effect of ORM-12741 will be evaluated on agitation/aggression symptoms and other neuropsychiatric symptoms. Furthermore, cognition and psychotic and depressive symptoms will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent (IC) for participation in the study (co-signed by the subject's next of kin or caregiver, or other legally acceptable representative.
- •Written IC obtained from a consistently available caregiver informant who is knowledgeable of the subject's condition and its progression and is willing to accompany the subject to all visits and supervise the administration of the study medication.
- •Age of 55-90 years (inclusive).
- •Male or female subjects with diagnosis of probable Alzheimer's Disease.
- •Brain imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) consistent with a diagnosis of Alzheimer's Disease (within 18 months or at screening).
- •Mini-mental state examination (MMSE) score between 10-24 (inclusive).
- •Clinically significant agitation meeting the International Psychogeriatric Association Provisional Criteria for Agitation in Cognitive Impairment. The agitation symptoms need to have been present for at least 4 weeks before the screening visit.
- •Neuropsychiatric Inventory agitation/aggression item score at least 4 at screening visit.
排除标准
- •Modified Hachinski Ischemia Score (MHIS) >
- •Changes in AChE inhibitor (donepezil, rivastigmine or galantamine) dosing within 2 months prior to screening.
- •Changes in memantine dosing within 2 months prior to the screening.
- •Changes in antidepressant dosing or addition of another antidepressant medication within 2 months prior to the screening.
- •Use of antipsychotics at any dose within 1 month prior to screening.
- •Use of benzodiazepines, other than short-acting sleep medications, for night at a maximum of 3 nights/week, within 2 months prior to screening.
- •Use of any anticholinergic medication within 2 months prior to screening.
- •Current use (within the 30 days prior to screening) of medications with known relevant alpha-2C AR affinity (e.g. mirtazapine, mianserin, clonidine, guanfacine or tizanidine) or with high noradrenaline transporter affinity (reboxetine, venlafaxine or duloxetine).
- •Current use of other psychotropic agents, unless the dosing has been stable during the last 2 months prior to the screening.
- •Myocardial infarction or other clinically significant ischemic cardiac disease, heart failure, or arrhythmia tendency within the past 2 years.
- •Current or history of malignancy within 5 years before screening.
- •Suicidal ideation in the 6 months before screening or current suicide risk based on the Colombia-Suicide Severity Rating Scale (C-SSRS) (items 4 and 5 exclusionary) or current risk of suicide based on the investigator's judgement.
- •Specific findings in MRI or CT that could in the opinion of the investigator affect cognitive function (such as cortical infarct or silent lacuna in a region known to affect cognition).
- •Supine heart rate < 48 bpm or > 100 bpm.
- •Systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg after a 5-minute rest.
- •Symptomatic orthostatic hypotension.
- •QTc-Fridericia (QTcF) repeatedly > 450 ms in males or > 470 ms in females.
- •Clinically significantly abnormal thyroid-stimulating hormone (TSH), vitamin B12 or folate serum levels at screening.
- •Resides in a skilled nursing facility.
研究组 & 干预措施
ORM-12741 high dose
Experimental
ORM-12741 high dose twice a day for 12 weeks.
干预措施: ORM-12741 (Drug)
ORM-12741 low dose
Experimental
ORM-12741 low dose twice a day for 12 weeks.
干预措施: ORM-12741 (Drug)
Placebo
Placebo Comparator
Placebo twice a day for 12 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale
时间窗: 12 weeks
次要结局
- Efficacy on aggression/agitation symptoms and overall clinical status measured by Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change(12 weeks)
- Plasma concentrations of ORM ORM-12741, metabolites and possible other Alzheimer's disease medication(12 weeks)
- Safety measured by electrocardiogram(12 weeks)
- Safety measured by laboratory variables(12 weeks)
- Safety measured by assessing adverse events(12 weeks)
- Safety measured by vital signs(12 weeks)
- Efficacy on daily living measured by Alzheimer's Disease Co-operative Study - Activities of Daily Living inventory(12 weeks)
- Efficacy on cognitive symptoms measured by Alzheimer's Disease Assessment Scale(12 weeks)
- Efficacy on cognitive symptoms measured by Cognitive Drug Research computerized test battery(12 weeks)
- Efficacy on aggression/agitation symptoms measured by Cohen Mansfield Agitation Inventory(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort StudyAlzheimer DiseaseNCT03554226University Hospital, Toulouse270
Unknown
不适用
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)Alzheimer's DiseaseNCT00703430Peking University50
已完成
不适用
Specific Interventions for Agitation in Alzheimer's DiseaseAlzheimer's DiseaseDementiaNCT00018291US Department of Veterans Affairs
招募中
2 期
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)Mild Cognitive ImpairmentAlzheimer DiseaseMemory ImpairmentNCT04601038Johns Hopkins University52
招募中
2 期
Treating Hyperexcitability in AD With LevetiracetamAlzheimer DementiaAlzheimer DiseaseDementia of Alzheimer TypeMild Cognitive ImpairmentNCT03875638Beth Israel Deaconess Medical Center85